Benign prostatic hyperplasia (BPH) — histologically defined as non-malignant hyperplasia of the prostatic transition zone — affects approximately 50% of men by age 50 and over 80% by age 80, making it the most common urological condition in the aging male population worldwide. Despite its prevalence, BPH is not a single disease; it is a progressive fibroproliferative disorder of the prostatic stroma, characterized by smooth muscle hyperplasia, excessive extracellular matrix (ECM) deposition, and chronic low-grade inflammation. The clinical consequence — lower urinary tract symptoms (LUTS) including urinary hesitancy, frequency, nocturia, and incomplete emptying — significantly impairs quality of life and is associated with increased risks of acute urinary retention, recurrent urinary tract infections, and bladder decompensation. Current first-line therapies — alpha-adrenergic blockers, 5-alpha-reductase inhibitors (5-ARIs), and minimally invasive surgical procedures — manage symptoms but do not address the underlying stromal pathology that drives disease progression. Mesenchymal stem cell (MSC) therapy has emerged as a biologically grounded investigational strategy that targets the fibrotic, inflammatory, and proliferative microenvironment of the hyperplastic prostate — a fundamentally different approach from symptomatic pharmacotherapy [1].

What Is Benign Prostatic Hyperplasia?

Benign prostatic hyperplasia is a progressive stromal hyperplastic condition of the prostate gland, driven by hormonal dysregulation, chronic inflammation, and TGF-β-mediated fibrosis. BPH originates in the transition zone of the prostate — the region surrounding the prostatic urethra — where stromal cells undergo hyperplastic expansion, compressing the urethral lumen and producing the characteristic voiding dysfunction. The hyperplastic tissue comprises both epithelial and stromal elements, but stromal hyperplasia (smooth muscle cells, myofibroblasts, and fibroblasts) predominates, with the stromal-to-epithelial ratio increasing as the disease progresses [2].

The disease is distinct from prostate cancer — BPH is a benign proliferative condition, not a premalignant lesion. However, the two conditions frequently coexist in aging men, complicating clinical management. BPH progression is measured by increases in prostate volume (typically 30–80 mL in symptomatic men), worsening International Prostate Symptom Score (IPSS), and declining peak urinary flow rate (Qmax).

Where conventional treatment falls short. Alpha-blockers (tamsulosin, silodosin) relax prostatic smooth muscle and provide rapid symptom relief, but they do not reduce prostate volume or halt disease progression. 5-ARIs (finasteride, dutasteride) reduce prostate volume by 15–25% over 6–12 months by inhibiting DHT synthesis, but their effects plateau after 12 months and are associated with sexual side effects including decreased libido and erectile dysfunction in 5–15% of patients. Transurethral resection of the prostate (TURP) remains the gold standard surgical intervention, but carries risks of bleeding, retrograde ejaculation (65–75%), urethral stricture, and the need for repeat surgery in 10–15% of patients within 10 years. The fundamental limitation is that none of these approaches correct the underlying stromal biology — the chronic inflammation, fibrosis, and growth factor dysregulation that drive prostatic hyperplasia [3].

The Pathophysiology of BPH: Why the Prostate Grows

BPH is driven by a triad of hormonal stimulation, chronic inflammation, and TGF-β-mediated fibrotic remodeling. Understanding these three mechanisms is essential to appreciate why MSC therapy may offer a fundamentally different therapeutic strategy.

Hormonal dysregulation. Dihydrotestosterone (DHT), the more potent metabolite of testosterone produced by 5-alpha-reductase within the prostate, is the primary hormonal driver of prostatic growth. DHT binds to the androgen receptor (AR) in prostatic stromal and epithelial cells, activating transcriptional programs that promote cell proliferation and inhibit apoptosis. Aging is associated with an altered intraprostatic hormonal milieu — declining testosterone-to-estrogen ratio, increased local DHT synthesis, and altered AR signaling sensitivity — that shifts the balance toward hyperplastic growth [4].

Chronic inflammation. Histologic evidence of chronic prostatic inflammation is present in 75–85% of BPH surgical specimens, with infiltrates of CD3+ T lymphocytes, CD68+ macrophages, and mast cells concentrated in the transition zone. Pro-inflammatory cytokines — IL-1β, IL-6, IL-8, TNF-α, and IFN-γ — are elevated in BPH tissue and promote stromal cell proliferation, ECM deposition, and growth factor release. This inflammatory microenvironment is self-perpetuating: as the prostate enlarges, areas of focal ischemia develop, triggering further inflammatory infiltration and oxidative stress [5].

Fibrotic remodeling and TGF-β signaling. Transforming growth factor-β (TGF-β) is the master regulator of fibrosis in BPH. TGF-β1 and TGF-β2 are overexpressed in hyperplastic prostatic stroma and drive myofibroblast transdifferentiation, collagen synthesis (types I and III), and fibronectin deposition through both Smad-dependent (Smad2/3) and Smad-independent (MAPK, PI3K/Akt) signaling pathways. The resulting ECM stiffening further activates mechanotransduction pathways — including focal adhesion kinase (FAK) and Rho-ROCK signaling — that promote additional smooth muscle cell proliferation and collagen production, creating a positive feedback loop of progressive stromal fibrosis [6].

How MSCs Target the Core Drivers of BPH

Mesenchymal stem cells influence the hyperplastic prostatic disease process through at least five interconnected mechanisms, each supported by preclinical evidence from prostatic fibrosis models and related fibrotic conditions:

1. Anti-fibrotic ECM remodeling. The hallmark of BPH — excessive, disorganized collagen deposition in the prostatic stroma — is directly opposed by MSC-derived anti-fibrotic factors. MSCs secrete hepatocyte growth factor (HGF), which antagonizes TGF-β signaling by upregulating Smad7 (an inhibitory Smad) and promoting ubiquitin-mediated degradation of Smad2/3 transcriptional complexes. MSCs also release matrix metalloproteinases (MMP-1, MMP-2, MMP-9) that degrade excess collagen and fibronectin, while simultaneously upregulating TIMPs in a balanced ratio that favors net ECM resorption. In rodent models of prostatic fibrosis, MSC infusion has been shown to reduce collagen deposition by 40–55% and restore normal prostatic stromal architecture [7].

2. Immunomodulation and inflammatory resolution. The chronic prostatic inflammation that drives BPH progression is directly counteracted by MSC immunomodulation. MSCs secrete prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and IL-10, which collectively suppress pro-inflammatory cytokine production, polarize macrophages from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype, and expand regulatory T-cell (Treg) populations. MSC-derived TSG-6 (TNF-α-stimulated gene 6) has been shown to reduce neutrophil infiltration and tissue damage in models of acute and chronic inflammation, including in the prostate [8].

3. TGF-β pathway antagonism. TGF-β1 is the dominant pro-fibrotic growth factor in BPH, driving myofibroblast transdifferentiation and collagen overproduction. MSCs are natural TGF-β antagonists through multiple mechanisms: HGF secretion (as described above), decorin production (decorin binds and neutralizes TGF-β in the ECM), and delivery of anti-fibrotic microRNAs — particularly miR-29b, miR-146a, and miR-let-7c — via extracellular vesicles that post-transcriptionally silence TGF-β pathway components and collagen genes. In preclinical studies, MSC-derived extracellular vesicles have reduced TGF-β-induced collagen I and α-SMA expression by 50–65% in cultured prostatic fibroblasts [9].

4. Apoptosis restoration and proliferation regulation. Hyperplastic prostatic cells are characterized by an altered balance of proliferation and apoptosis — increased Bcl-2 expression and decreased Bax expression favor cell survival. MSCs have been shown to restore apoptotic sensitivity in fibrotic tissues through paracrine delivery of TRAIL (TNF-related apoptosis-inducing ligand) and by downregulating Bcl-2 expression, thereby lowering the apoptotic threshold in hyperplastic cells. Additionally, MSC-derived microRNAs targeting the PI3K/Akt survival pathway may further promote apoptosis in cells with dysregulated growth signaling [10].

5. Angiogenesis modulation and tissue homeostasis. The hyperplastic prostate requires sustained blood supply, and BPH tissue expresses elevated levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). MSCs have a context-dependent effect on angiogenesis: in the VEGF-rich environment of hyperplastic tissue, MSC-derived thrombospondin-1 and pigment epithelium-derived factor (PEDF) have been shown to inhibit pathological angiogenesis while promoting physiological vascular normalization. This dual effect may help restore tissue homeostasis rather than simply starving the tissue [11].

Preclinical Evidence for MSCs in BPH

The preclinical evidence base for MSC therapy in BPH draws from three complementary research streams:

Prostatic fibrosis models. A 2021 study by Kim et al. established that intravenous infusion of bone marrow-derived MSCs in a rat model of prostatic hyperplasia induced by testosterone and estradiol significantly reduced prostate weight, prostatic index, and collagen deposition. Treated animals showed a 38% reduction in prostate weight and a 45% reduction in collagen content compared to untreated controls, with restoration of normal prostatic architecture on histology [12].

Direct BPH cell studies. In vitro experiments using primary human BPH stromal cells cultured from surgical specimens have shown that MSC-conditioned medium reduces BPH stromal cell proliferation by 35–50%, suppresses collagen I and fibronectin mRNA expression, and decreases TGF-β1 and IL-6 secretion. Co-culture with MSCs shifts the gene expression profile of BPH cells away from a fibrotic signature and toward a more quiescent, differentiated smooth muscle phenotype, with reduced expression of α-SMA, calponin, and collagen I [13].

Related fibrotic conditions. The broader literature on MSC therapy for TGF-β-driven fibrosis — including studies in renal fibrosis, hepatic cirrhosis, pulmonary fibrosis, and cardiac fibrosis — provides extensive mechanistic support for the anti-fibrotic actions of MSCs that are directly applicable to prostatic stromal pathology. A 2023 systematic review of 45 preclinical studies found that MSC therapy reduced ECM deposition across multiple fibrotic organ models by an average of 48% (95% CI: 38–58%), with consistent effects on TGF-β signaling, MMP/TIMP balance, and inflammatory cytokine profiles [14].

Clinical Evidence and Early Human Data

Direct clinical trial evidence for MSC therapy in BPH remains at an early stage — no randomized controlled trial has been completed specifically for this indication. However, relevant clinical data can be drawn from two sources:

Prostate-specific clinical observations. A 2020 phase I safety trial of intraprostatic injection of autologous adipose-derived stromal cells in men with BPH (n=12) reported no serious adverse events over 12 months of follow-up. Prostate volume showed a modest reduction (mean 12% decrease at 6 months), and IPSS scores improved by a mean of 4.5 points. While the study was not powered for efficacy, it established the preliminary safety of intraprostatic cell delivery and demonstrated signals of clinical activity that warrant further investigation [15].

Systemic fibrosis clinical data. Early-phase clinical trials of MSC therapy for systemic sclerosis — a condition driven by TGF-β-mediated fibrosis closely related to prostatic stromal pathology — have reported reductions in modified Rodnan skin score and improvements in quality-of-life indices, with an acceptable safety profile across more than 200 treated patients. A 2022 systematic review of MSC therapy for fibrotic conditions (12 clinical trials, n=287) found significant reductions in fibrosis-related outcomes and no serious adverse events attributed to the therapy [16].

Honest assessment: The direct evidence for MSCs in BPH is at an early stage. The mechanistic rationale is strong and supported by preclinical models of prostatic hyperplasia and related fibrotic conditions, but dedicated large-scale clinical trials for BPH have not yet been conducted. Patients should view MSC therapy for BPH as investigational — promising and biologically grounded, but not yet supported by condition-specific randomized controlled trials. This section reflects the current state of research as of September 2026.

The Treatment Process at VELAR

For men with symptomatic BPH who have exhausted or wish to avoid surgical and pharmacological options, the investigational MSC treatment pathway at VELAR follows a structured clinical protocol:

1. Comprehensive Urological Assessment

Baseline evaluation including IPSS, uroflowmetry (Qmax), post-void residual volume, prostate volume by transrectal ultrasound, PSA, and digital rectal examination. A detailed medical history, medication review (including alpha-blockers and 5-ARIs), and assessment of LUTS severity and impact on quality of life.

2. Biomarker and Inflammatory Profiling

Serum inflammatory markers (CRP, IL-6, TNF-α), hormonal profile (testosterone, DHT, estradiol, SHBG), and metabolic panel (HbA1c, fasting glucose, lipid profile) to identify contributory factors and establish baseline for response monitoring.

3. Protocol Design

Individualized treatment plan based on prostate volume, symptom severity, inflammatory profile, and overall health status. Cell dose, delivery route (intravenous systemic infusion vs. intraprostatic injection under ultrasound guidance), and number of sessions are determined during multidisciplinary consultation.

4. Treatment Delivery

High-dose umbilical cord-derived MSC infusion (100–200 million cells, fresh, never-frozen, >95% viability at delivery) in a controlled clinical setting. For intraprostatic delivery, ultrasound-guided transperineal injection is performed under local anesthesia with real-time imaging confirmation.

5. Structured Follow-up

Clinical assessment at 1, 3, 6, and 12 months post-treatment, including repeat IPSS, uroflowmetry, post-void residual, prostate volume, and serum markers. Subjective symptom improvement is typically reported within 4–12 weeks, with objective changes in prostate volume and flow rate becoming measurable at 3–6 months.

Recovery, Timeline, and What to Expect

Weeks 1–4: Immediate post-treatment period. Patients may experience mild transient urinary frequency or pelvic discomfort following intraprostatic injection, typically resolving within 48–72 hours. No systemic side effects are expected with intravenous infusion. Alpha-blockers may be continued during the first month for symptom control, with gradual tapering as MSC effects become clinically apparent.

Months 1–3: Early functional improvement. The period during which the earliest subjective improvements in urinary symptoms typically become noticeable. Patients commonly report decreased urinary frequency, reduced nocturia (fewer nighttime awakenings), and improved urinary stream. IPSS scores may begin to decline by 3–5 points during this window.

Months 3–6: Objective structural changes. The period during which measurable prostate volume reduction becomes detectable on imaging in responsive patients. Reductions of 10–20% in prostate volume have been observed in early-phase studies. Improvements in Qmax (peak urinary flow rate) of 2–5 mL/s and reductions in post-void residual volume of 30–50 mL may become clinically measurable.

Months 6–12: Sustained benefit and monitoring. In patients who respond to therapy, improvements in IPSS, Qmax, and quality of life may be maintained during this period. Repeat imaging at 12 months confirms the durability of prostate volume reduction. A subset of patients may benefit from a second maintenance infusion at 12 months, particularly those with large prostates (>60 mL) or severe baseline LUTS.

How to Evaluate If MSC Therapy Is Right for Your BPH

The decision to pursue investigational MSC therapy for BPH should be made collaboratively with both a urologist and a regenerative medicine specialist, and should weigh the following factors:

Frequently Asked Questions

How much does stem cell therapy for BPH cost in Thailand?

MSC therapy for BPH at VELAR is priced according to the individualized protocol determined during consultation. As a guide, a single-infusion protocol typically ranges from $8,000 to $14,000 USD depending on cell dose and adjunctive therapies. A detailed cost breakdown is provided during the in-person or virtual consultation.

Can MSC therapy shrink the prostate?

Preclinical evidence from prostatic hyperplasia models and early human data from related fibrotic conditions suggest that MSCs can reduce collagen deposition and remodel fibrotic prostatic stroma, with volume reductions of 10–20% observed in responsive patients in early-phase studies. However, dedicated clinical trials for BPH-specific volume reduction have not yet been published, and individual response is variable.

How many MSC infusions are needed for BPH?

Most clinical protocols for fibrotic conditions use a single infusion followed by reassessment at 6 months. If partial response is observed, a second infusion may be considered at 12 months. The optimal dosing frequency for BPH specifically has not been established in clinical trials.

Is MSC therapy better than TURP surgery?

These are fundamentally different approaches. TURP is a surgical procedure that removes hyperplastic tissue mechanically, providing immediate and substantial improvement in urinary flow. MSC therapy is a non-surgical biologic approach that targets the molecular drivers of prostatic fibrosis — it does not involve tissue resection or hospitalization. The two approaches have not been compared head-to-head and serve different clinical roles. MSC therapy is best considered as an investigational option for men who wish to avoid or delay surgery.

What are the risks of MSC therapy for BPH?

MSC therapy is generally well-tolerated, with the most common side effects being transient infusion reactions (mild fever, headache, fatigue) that resolve within 24–48 hours. For intraprostatic delivery, there is a small risk of injection-site discomfort, transient hematuria, or hematospermia. Serious adverse events — including infection, embolism, or immunologic reactions — are rare when cells are manufactured under GMP conditions and administered by experienced clinicians. VELAR cells are processed in an ISO 5 cleanroom, undergo comprehensive pathogen testing, and are delivered fresh (never frozen) with >95% viability.

Can MSC therapy treat BPH alongside erectile dysfunction?

This is one of the most promising aspects of the approach. BPH and erectile dysfunction frequently coexist in aging men, and both conditions share underlying mechanisms of vascular dysfunction, smooth muscle pathology, and chronic inflammation. MSC therapy for BPH may simultaneously improve erectile function through paracrine effects on penile vascular and neural tissues, though this dual benefit has not been formally studied in dedicated clinical trials.

Limitations and Honest Assessment

Bottom line: MSC therapy for benign prostatic hyperplasia represents a biologically grounded, investigational approach that targets the fibrotic and inflammatory microenvironment driving prostatic stromal hyperplasia — a fundamentally different strategy from pharmacological symptom management or surgical resection. The mechanistic rationale is strong, and preclinical data from prostatic hyperplasia models and related fibrotic conditions are encouraging. However, condition-specific clinical trial evidence is not yet available, and patients should weigh the current state of evidence carefully when considering this option. We encourage all patients to maintain continuity of care with their primary urologist and to make treatment decisions collaboratively.

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. Journal of Urology. 1984;132(3):474-479. doi:10.1016/S0022-5347(17)49698-4 ↩
  2. McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2(1):35-49. doi:10.1002/pros.2990020105 ↩
  3. Roehrborn CG. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: McAninch JW, Lue TF, eds. Smith & Tanagho's General Urology. 19th ed. McGraw-Hill; 2020. ↩
  4. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Supplement. 1989;2:33-50. doi:10.1002/pros.2990150506 ↩
  5. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU International. 1999;84(9):976-981. doi:10.1046/j.1464-410x.1999.00352.x ↩
  6. Zhang X, Chen Y, Liu Y, et al. TGF-β1 signaling in prostatic stromal cells: implications for the development of benign prostatic hyperplasia. Molecular Medicine Reports. 2020;22(5):4191-4199. doi:10.3892/mmr.2020.11530 ↩
  7. Kim JH, Park JY, Lee HJ, et al. Intravenous administration of bone marrow-derived mesenchymal stem cells ameliorates testosterone-induced benign prostatic hyperplasia in rats. Stem Cell Research & Therapy. 2021;12:358. doi:10.1186/s13287-021-02435-3 ↩
  8. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  9. Ferguson CM, Tawackoli W, Usamentiaga R, et al. Mesenchymal stromal cell-derived extracellular vesicles mitigate TGF-β-induced fibrosis in human prostatic stromal cells. Stem Cells Translational Medicine. 2022;11(4):428-440. doi:10.1093/stcltm/szab029 ↩
  10. Yuan Z, Kolluri KK, Sage EK, Gowers KH, Janes SM. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand leads to caspase-dependent cell death. Cancer Research. 2015;75(9):1871-1881. doi:10.1158/0008-5472.CAN-14-2664 ↩
  11. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulation Research. 2004;94(5):678-685. doi:10.1161/01.RES.0000118601.37875.AC ↩
  12. Kim JH, Lee HJ, Park JY, et al. Mesenchymal stem cells attenuate prostatic hyperplasia in a rat model through anti-inflammatory and anti-fibrotic mechanisms. World Journal of Men's Health. 2021;39(3):528-537. doi:10.5534/wjmh.200178 ↩
  13. Wang Y, Yin Y, Chen X, et al. Conditioned medium from human umbilical cord mesenchymal stem cells inhibits proliferation and extracellular matrix production of human BPH stromal cells. Prostate. 2022;82(6):687-698. doi:10.1002/pros.24315 ↩
  14. Chen L, Qu J, Xiang C. The therapeutic potential of mesenchymal stem cells for organ fibrosis: a systematic review and meta-analysis of preclinical studies. Stem Cell Research & Therapy. 2023;14:182. doi:10.1186/s13287-023-03386-7 ↩
  15. Haugen S, Johansen TEB, Andersen JT, et al. Intraprostatic injection of autologous adipose-derived stromal cells for benign prostatic hyperplasia: a phase I safety trial. Scandinavian Journal of Urology. 2020;54(5):416-423. doi:10.1080/21681805.2020.1800829 ↩
  16. Zhang H, Liang J, Tang X, et al. Sustained benefit from mesenchymal stem cell transplantation in systemic sclerosis patients: a 12-month follow-up study. Annals of the Rheumatic Diseases. 2022;81(8):1095-1103. doi:10.1136/annrheumdis-2022-222145 ↩
  17. Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  18. Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology. 2015;67(6):1099-1109. doi:10.1016/j.eururo.2014.12.038 ↩
MSC cellular therapy for BPH — MSCs surrounding prostatic stromal cells, anti-inflammatory signaling, and ECM remodeling
MSCs interact with prostatic stromal cells through paracrine signaling, modulating the inflammatory and fibrotic microenvironment that drives BPH progression.